TY - JOUR
T1 - A global research priority agenda to advance public health responses to fatty liver disease
AU - Healthy Livers, Healthy Lives Collaborators
AU - Lazarus, Jeffrey V.
AU - Mark, Henry E.
AU - Allen, Alina M.
AU - Arab, Juan Pablo
AU - Carrieri, Patrizia
AU - Noureddin, Mazen
AU - Alazawi, William
AU - Alkhouri, Naim
AU - Alqahtani, Saleh A.
AU - Arrese, Marco
AU - Bataller, Ramon
AU - Berg, Thomas
AU - Brennan, Paul N.
AU - Burra, Patrizia
AU - Castro-Narro, Graciela E.
AU - Cortez-Pinto, Helena
AU - Cusi, Kenneth
AU - Dedes, Nikos
AU - Duseja, Ajay
AU - Francque, Sven M.
AU - Hagström, Hannes
AU - Huang, Terry T.K.
AU - Wajcman, Dana Ivancovsky
AU - Kautz, Achim
AU - Kopka, Christopher J.
AU - Krag, Aleksander
AU - Miller, Veronica
AU - Newsome, Philip N.
AU - Rinella, Mary E.
AU - Romero, Diana
AU - Sarin, Shiv Kumar
AU - Silva, Marcelo
AU - Spearman, C. Wendy
AU - Tsochatzis, Emmanuel A.
AU - Valenti, Luca
AU - Villota-Rivas, Marcela
AU - Zelber-Sagi, Shira
AU - Schattenberg, Jörn M.
AU - Wong, Vincent Wai Sun
AU - Younossi, Zobair M.
AU - Huang, Terry T.K.
AU - Aberg, Fredrik
AU - Adams, Leon
AU - Al-Naamani, Khalid
AU - Albadawy, Reda M.
AU - Alexa, Zinaida
AU - Allison, Michael
AU - Alnaser, Faisal A.
AU - Alswat, Khalid
AU - Alvares-da-Silva, Mario Reis
AU - Alvaro, Domenico
AU - Alves-Bezerra, Michele
AU - Andrade, Raul J.
AU - Anstee, Quentin M.
AU - Awuku, Yaw Asante
AU - Baatarkhuu, Oidov
AU - Baffy, Gyorgy
AU - Bakieva, Shokhista
AU - Bansal, Meena B.
AU - Barouki, Robert
AU - Batterham, Rachel L.
AU - Behling, Cynthia
AU - Belfort-DeAguiar, Renata
AU - Berzigotti, Annalisa
AU - Betel, Michael
AU - Bianco, Cristiana
AU - Bosi, Emanuele
AU - Boursier, Jerome
AU - Brunt, Elizabeth M.
AU - Bugianesi, Elisabetta
AU - Byrne, Christopher J.
AU - Cabrera Cabrejos, Maria Cecilia
AU - Caldwell, Stephen
AU - Carr, Rotonya
AU - Castellanos Fernández, Marlen Ivón
AU - Castera, Laurent
AU - Castillo-López, Maria Gabriela
AU - Caussy, Cyrielle
AU - Cerda-Reyes, Eira
AU - Ceriello, Antonio
AU - Chan, Wah Kheong
AU - Chang, Yoosoo
AU - Charatcharoenwitthaya, Phunchai
AU - Chavez-Tapia, Norberto
AU - Chung, Raymond T.
AU - Colombo, Massimo
AU - Coppell, Kirsten
AU - Cotrim, Helma P.
AU - Craxi, Antonio
AU - Crespo, Javier
AU - Dassanayake, Anuradha
AU - Davidson, Nicholas O.
AU - De Knegt, Robert
AU - de Ledinghen, Victor
AU - Demir, Münevver
AU - Desalegn, Hailemichael
AU - Diago, Moises
AU - Dillon, John F.
AU - Dimmig, Bruce
AU - Dirac, M. Ashworth
AU - Dirchwolf, Melisa
AU - Dufour, Jean François
AU - Dvorak, Karel
AU - Ekstedt, Mattias
AU - El-Kassas, Mohamed
AU - Elsanousi, Osama M.
AU - Elsharkawy, Ahmed M.
AU - Elwakil, Reda
AU - Eskridge, Wayne
AU - Eslam, Mohammed
AU - Esmat, Gamal
AU - Fan, Jian Gao
AU - Ferraz, Maria Lucia
AU - Flisiak, Robert
AU - Fortin, Davide
AU - Fouad, Yasser
AU - Freidman, Scott L.
AU - Fuchs, Michael
AU - Gadano, Adrian
AU - Gastaldelli, Amalia
AU - Geerts, Anja
AU - Geier, Andreas
AU - George, Jacob
AU - Gerber, Lynn H.
AU - Ghazinyan, Hasmik
AU - Gheorghe, Liana
AU - Kile, Denise Giangola
AU - Girala, Marcos
AU - Boon Bee, George Goh
AU - Goossens, Nicolas
AU - Graupera, Isabel
AU - Grønbæk, Henning
AU - Hamid, Saeed
AU - Hebditch, Vanessa
AU - Henry, Zachary
AU - Hickman, Ingrid J.
AU - Hobbs, L. Ansley
AU - Hocking, Samantha L.
AU - Hofmann, Wolf Peter
AU - Idilman, Ramazan
AU - Iruzubieta, Paula
AU - Isaacs, Scott
AU - Isakov, Vasily A.
AU - Ismail, Mona H.
AU - Jamal, Mohammad H.
AU - Jarvis, Helen
AU - Jepsen, Peter
AU - Jornayvaz, François
AU - Sudhamshu, K. C.
AU - Kakizaki, Satoru
AU - Karpen, Saul
AU - Kawaguchi, Takumi
AU - Keating, Shelley E.
AU - Khader, Yousef
AU - Kim, Seung Up
AU - Kim, Won
AU - Kleiner, David E.
AU - Koek, Ger
AU - Joseph Komas, Narcisse Patrice
AU - Kondili, Loreta A.
AU - Koot, Bart G.
AU - Korenjak, Marko
AU - Kotsiliti, Eleni
AU - Koulla, Yiannoula
AU - Kugelmas, Carina
AU - Kugelmas, Marcelo
AU - Labidi, Asma
AU - Lange, Naomi F.
AU - Lavine, Joel E.
AU - Lazo, Mariana
AU - Leite, Nathalie
AU - Lin, Han Chieh
AU - Lkhagvaa, Undram
AU - Long, Michelle T.
AU - Lopez-Jaramillo, Patricio
AU - Lozano, Adelina
AU - Macedo, Maria Paula
AU - Malekzadeh, Reza
AU - Marchesini, Giulio
AU - Marciano, Sebastian
AU - Martinez, Kim
AU - Martínez Vázquez, Sophia E.
AU - Mateva, Lyudmila
AU - Mato, José M.
AU - Nlombi, Charles Mbendi
AU - McCary, Alexis Gorden
AU - McIntyre, Jeff
AU - McKee, Martin
AU - Mendive, Juan M.
AU - Mikolasevic, Ivana
AU - Miller, Pamela S.
AU - Milovanovic, Tamara
AU - Milton, Terri
AU - Moreno-Alcantar, Rosalba
AU - Morgan, Timothy R.
AU - Motala, Ayesha
AU - Muris, Jean
AU - Musso, Carla
AU - Nava-González, Edna J.
AU - Negro, Francesco
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2023/9
Y1 - 2023/9
N2 - Background & aims: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. Methods: Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. Results: The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of ‘agree’ responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement (‘agree’ + ‘somewhat agree’); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% ‘agree’), 13 priorities had <80% ‘agree’, with greater reliance on ‘somewhat agree’ to achieve >90% combined agreement. Conclusions: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. Impact and implications: An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat.
AB - Background & aims: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. Methods: Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. Results: The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of ‘agree’ responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement (‘agree’ + ‘somewhat agree’); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% ‘agree’), 13 priorities had <80% ‘agree’, with greater reliance on ‘somewhat agree’ to achieve >90% combined agreement. Conclusions: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. Impact and implications: An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat.
KW - Delphi method
KW - Global health
KW - NAFLD/NASH
KW - Non-communicable disease (NCD)
KW - Steatotic liver disease
UR - http://www.scopus.com/inward/record.url?scp=85165924387&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2023.04.035
DO - 10.1016/j.jhep.2023.04.035
M3 - Article
C2 - 37353401
AN - SCOPUS:85165924387
SN - 0168-8278
VL - 79
SP - 618
EP - 634
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 3
ER -